<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872206</url>
  </required_header>
  <id_info>
    <org_study_id>HPN536-2001</org_study_id>
    <nct_id>NCT03872206</nct_id>
  </id_info>
  <brief_title>Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression</brief_title>
  <official_title>A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harpoon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harpoon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability&#xD;
      and PK in patients with advanced cancers associated with mesothelin expression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess initial safety and determination of recommended Phase 2 dose: Dose limiting toxicity</measure>
    <time_frame>Up to study day 21</time_frame>
    <description>Dose limiting toxicity measured by adverse events and serious adverse events will be reviewed by dose level by the Safety Oversight Committee and will result in a recommended Phase 2 dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of HPN536 at the recommended Phase 2 dose: overall response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate overall response rate (ORR) as assessed by RECIST</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Advanced Cancers Associated With Mesothelin Expression</condition>
  <arm_group>
    <arm_group_label>HPN536-2001 - Part 1 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 (Dose Escalation): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic adenocarcinoma, or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion with a fix dose. Dose escalation per cohort until an estimated therapeutic dose level has been reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPN536-2001 - Part 2 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 (Dose Expansion): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, malignant mesothelioma, pancreatic adenocarcinoma or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion.&#xD;
Group 1: Eligible patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.&#xD;
Group 2: Eligible patients with pancreatic adenocarcinoma.&#xD;
Group 3: Eligible patients with mesothelioma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPN536</intervention_name>
    <description>Dose escalation: HPN536 will be administered once weekly via IV infusion Dose expansion: HPN536 will be administered at the RP2D once weekly via IV infusion</description>
    <arm_group_label>HPN536-2001 - Part 1 (Dose Escalation)</arm_group_label>
    <arm_group_label>HPN536-2001 - Part 2 (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Patients ≥18 years of age&#xD;
&#xD;
          2. One of the following progressive advanced or metastatic cancers:&#xD;
&#xD;
               1. Epithelial ovarian, fallopian tube, or primary peritoneal cancer (Part 1 and Part&#xD;
                  2, Group 1 only) that is platinum refractory or platinum resistant&#xD;
&#xD;
               2. Pancreatic adenocarcinoma (Part 1 and Part 2, Group 2 only) that is locally&#xD;
                  advanced, and now with progressive disease on or after front-line treatment&#xD;
&#xD;
               3. Malignant mesothelioma with epithelioid histology, pleural (Part 1 and Part 2,&#xD;
                  Group 3 only) or primary peritoneal (Part 1 and Part 2, Group 3 only)&#xD;
&#xD;
          3. For Part 2 only - Measurable disease according to RECIST v1.1 for patients with&#xD;
             epithelial ovarian, fallopian tube, or primary peritoneal cancer, pancreatic&#xD;
             adenocarcinoma, and peritoneal mesothelioma, and mRECIST v1.1 for patients with&#xD;
             pleural mesothelioma&#xD;
&#xD;
          4. Available archival tissue sample or fresh biopsy tissue sample must be obtained prior&#xD;
             to enrollment&#xD;
&#xD;
          5. For patients previously treated with systemic chemotherapy, targeted therapy,&#xD;
             immunotherapy, or treatment with an investigational anticancer agent, discontinuation&#xD;
             must have occurred ≥2 weeks, or at least 5 half-lives, whichever is longer, prior to&#xD;
             start of study drug. The maximum washout period will not exceed 4 weeks&#xD;
&#xD;
          6. ECOG performance status of 0 or 1&#xD;
&#xD;
          7. Adequate bone marrow function, including:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1500/mm3 or ≥1.5 x 109/L&#xD;
&#xD;
               2. Platelets ≥100,000/mm3 or ≥100 x 109/L&#xD;
&#xD;
               3. Hemoglobin (Hgb) ≥10 g/dL&#xD;
&#xD;
          8. Adequate renal function, including estimated creatinine clearance ≥30 mL/min&#xD;
&#xD;
          9. Adequate liver function, including:&#xD;
&#xD;
               1. Total serum bilirubin ≤1.5 x upper limit of normal (ULN) unless the patient has&#xD;
                  documented Gilbert syndrome in which case the maximum total serum bilirubin&#xD;
                  should be &lt;5 mg/dL&#xD;
&#xD;
               2. Aspartate and alanine transaminase (AST and ALT) ≤2.5 x ULN or AST/ALT ≤5 x ULN&#xD;
                  for patients with liver metastases&#xD;
&#xD;
         10. Serum albumin as follows:&#xD;
&#xD;
               1. ≥30 mg/mL for patients with epithelial ovarian cancer, fallopian tube cancer,&#xD;
                  primary peritoneal cancer, or mesothelioma&#xD;
&#xD;
               2. Within normal limits for patients with pancreatic adenocarcinoma&#xD;
&#xD;
         11. Patients with pancreatic adenocarcinoma: C-reactive protein (CRP) within normal limits&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Previously treated or current brain metastases. Note: Patients with previously treated&#xD;
             brain metastases may participate provided they are clinically stable for at least 4&#xD;
             weeks prior to study entry and have no evidence of new or enlarging brain metastases&#xD;
&#xD;
          2. Concurrent treatment with anti- TNFα therapies, systemic corticosteroids, or other&#xD;
             immune suppressive drugs within the 2 weeks prior to Screening&#xD;
&#xD;
          3. Patients with pancreatic adenocarcinoma: Any ascites within 1 month prior to screening&#xD;
&#xD;
          4. History of or known or suspected autoimmune disease&#xD;
&#xD;
          5. History of clinically significant cardiovascular disease&#xD;
&#xD;
          6. Pulmonary, hematologic, renal, hepatic, gastrointestinal, neurological or psychiatric&#xD;
             disease that would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harpoon Therapeutics</last_name>
    <phone>(650) 443-7400</phone>
    <email>HPN5362001@harpoontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ahn, MD</last_name>
      <phone>480-342-2000</phone>
      <email>Ahn.Daniel@Mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Martinez</last_name>
      <email>Lorraine.Martinez@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7170</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <phone>310-794-6500</phone>
      <email>LYonemoto@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Colon-Otero, MD</last_name>
      <phone>904-953-2000</phone>
      <email>Gcolonotero@Mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Wahner Hendrickson, MD</last_name>
      <phone>507-284-2511</phone>
      <email>WahnerHendrickson.Andrea@Mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Ezell</last_name>
      <phone>314-273-3899</phone>
      <email>Casey.ezell@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Perron</last_name>
      <email>perronV@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Shepard, MD</last_name>
      <phone>216-445-5670</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephenson Cancer Center</last_name>
      <phone>405-271-8778</phone>
      <email>PhaseI-Referrals@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Mcdougall</last_name>
      <phone>215-503-1011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Institute</last_name>
    </contact>
    <contact_backup>
      <phone>1-844-482-4812</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Crowley Cancer Research</last_name>
      <phone>972-566-3000</phone>
      <email>Referral@MaryCrowley.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Tsvetkova</last_name>
      <phone>206-606-1646</phone>
      <email>otsvetkova@seattlecca.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

